Mardepodect

Drug Profile

Mardepodect

Alternative Names: MP-10; PF-02545920; PF-2545920

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antipsychotics; Pyrazoles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Discontinued Schizophrenia

Most Recent Events

  • 01 Oct 2016 Pfizer completes a phase II trial in Huntington's disease in USA, Canada, Germany, Poland and the United Kingdom (NCT02197130)
  • 02 Aug 2016 Discontinued - Phase-II for Schizophrenia (Adjunctive treatment) in USA (PO) (Pfizer pipeline, August 2016)
  • 01 Feb 2015 Pfizer initiates enrolment in a phase II extension trial in Huntington's disease in USA (NCT02342548)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top